Two Sigma Securities’s Protagenic Therapeutics Warrant PTIXW Stock Holding History

Two Sigma Securities’s Portfolio PTIXW Stock Details PTIXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,533	Closed	-$371	–	2094
2025 Q4	$371	Buy	15,533 +3,181	+26%	+$94	﹤0.01%	1406
2025 Q3	$316	Buy	12,352 +1,110	+10%	+$53	﹤0.01%	1309
2025 Q2	$536	Buy	+11,242	New	+$406	﹤0.01%	1420
2025 Q1	–	Sell	-17,500	Closed	-$61	–	2057
2024 Q4	$61	Buy	+17,500	New	+$156	﹤0.01%	1543

Two Sigma Securities's PTIXW Position: Q1 2026 in Review

Two Sigma Securities sold out of Protagenic Therapeutics Warrant (PTIXW) in Q1 2026, closing a stake of 15,533 shares — an estimated $371 sold.

Two Sigma Securities first reported a position in PTIXW in Q4 2024 and held it in 4 quarters. The position peaked at $536 in Q2 2025. 0 funds tracked by Wall St. Rank hold PTIXW as of Q1 2026.

Two Sigma Securities reported no remaining Protagenic Therapeutics Warrant position as of Q1 2026 after selling out during the quarter.
Two Sigma Securities sold 15,533 Protagenic Therapeutics Warrant shares in Q1 2026, an estimated $371.
Two Sigma Securities first reported a position in Protagenic Therapeutics Warrant in Q4 2024 and held it in 4 quarters.
Two Sigma Securities's Protagenic Therapeutics Warrant position peaked at $536 in Q2 2025.
0 funds tracked by Wall St. Rank held Protagenic Therapeutics Warrant as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.